Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0035412 (
rhabdomyosarcoma
)
6,156
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The applicability of five different rodent tumors for experimental PET has been investigated. L-[1-11C]Tyrosine was a better indicator for the growth activity of the tumors than [18F]
FDG
. For experimental PET, the three mice models studied appeared inappropriate; the Lewis lung tumor and the fibrosarcomateous FIO 26 had too low a tyrosine utilization, while the lymphosarcomateous LY showed insufficient tumor-to-background ratios. Of the two rat models, the necrotic Walker 256 carcinosarcoma was less suitable. By using L-[1-11C]tyrosine, the solid,
rhabdomyosarcoma
tumor offers good possibilities of monitoring therapeutic interventions with PET.
...
PMID:Suitability of rodent tumor models for experimental PET with L-[1-11C]tyrosine and 2-[18F]fluoro-2-deoxy-D-glucose. 191 20
Three patients with primary breast sarcoma showed intense F-18
FDG
breast uptake on the whole-body scan. In two patients the uptake was irregular and associated with cold foci that corresponded to hypodense lesions noted on the chest CT; these represented areas of pathologically demonstrated tumor necrosis. There was also intense
FDG
uptake in pulmonary, axillary, and supraclavicular lymph node metastases. All lesions were confirmed by CT scan of the chest. Thus F-18
FDG
positron emission tomographic scanning accurately staged the tumors in these two patients, and it documented local recurrence in the third patient. Histopathologic examination showed evidence of a high-grade sarcoma, a primary
rhabdomyosarcoma
, and a malignant cystosarcoma phyllodes of the breast. Similar to breast carcinoma, F-18
FDG
whole-body positron emission tomographic imaging could be useful in diagnosing and staging primary breast sarcomas.
...
PMID:F-18 FDG whole-body positron emission tomography scan in primary breast sarcoma. 973 83
Anti-Hu syndrome is a paraneoplastic neurological syndrome, most frequently associated with small cell carcinoma of the lung. Subacute sensory neuronopathy is thought to be the most frequent presentation of the anti-Hu syndrome, but it seems that sensory-motor neuropathy is the most common form in the anti-Hu neuropathy. Neurological symptoms often appear before the associated cancer has been identified. Sometimes the tumor is discovered months or even a few years after the appearance of the neurological syndrome.
FDG
-PET scan seems a better method for finding the tumor in patients with paraneoplastic neurological syndrome and anti-Hu antibodies who had negative test results after an initial workup using radiological methods. In this case report we present a patient with the anti-Hu syndrome associated with an unclassified
rhabdomyosarcoma
with epitheloid cellular morphology and neuroendocrine differentiation.
...
PMID:Unclassified rhabdomyosarcoma in a patient with anti-Hu syndrome. 1639 22
Soft-tissue sarcomas spread predominantly to the lung and it is unclear how often
FDG
-PET scans will detect metastases not already obvious by chest CT scan or clinical examination. Adult limb and body wall soft-tissue sarcoma cases were identified retrospectively. Ewing's sarcoma,
rhabdomyosarcoma
, GIST, desmoid tumors, visceral tumors, bone tumors, and retroperitoneal sarcomas were excluded as were patients imaged for followup, response assessment, or recurrence. All patients had a diagnostic chest CT scan. 109 patients met these criteria, 87% of which had intermediate or high-grade tumors. The most common pathological diagnoses were leiomyosarcoma (17%), liposarcoma (17%), and undifferentiated or pleomorphic sarcoma (16%). 98% of previously unresected primary tumors were
FDG
avid. PET scans were negative for distant disease in 91/109 cases. The negative predictive value was 89%. Fourteen PET scans were positive. Of these, 6 patients were already known to have metastases, 3 were false positives, and 5 represented new findings of metastasis (positive predictive value 79%). In total, 5 patients were upstaged by
FDG
-PET (4.5%). Although PET scans may be of use in specific circumstances, routine use of
FDG
PET imaging as part of the initial staging of soft-tissue sarcomas was unlikely to alter management in our series.
...
PMID:FDG PET/CT in Initial Staging of Adult Soft-Tissue Sarcoma. 2325 Oct 96
An 18F-
FDG
PET/CT scan was performed in a 26-year-old man with a known alveolar
rhabdomyosarcoma
for staging. The PET/CT scan showed abnormally increased
FDG
activity involving almost all bones in the imaged regions. In contrast, 99mTc-MDP whole-body bone scan demonstrated only very limited bone metastases.
...
PMID:Bone marrow metastases from alveolar rhabdomyosarcoma with impressive FDG PET/CT finding but less-revealing bone scintigraphy. 2415 40
Anticalins are a novel class of targeted protein therapeutics. The PEGylated Anticalin Angiocal (PRS-050-PEG40) is directed against VEGF-A. The purpose of our study was to compare the performance of diffusion weighted imaging (DWI), dynamic contrast enhanced magnetic resonance imaging (DCE)-MRI and positron emission tomography with the tracer [18F]fluorodeoxyglucose (
FDG
-PET) for monitoring early response to antiangiogenic therapy with PRS-050-PEG40. 31 mice were implanted subcutaneously with A673
rhabdomyosarcoma
xenografts and underwent DWI, DCE-MRI and
FDG
-PET before and 2 days after i.p. injection of PRS-050-PEG40 (n = 13), Avastin (n = 6) or PBS (n = 12). Tumor size was measured manually with a caliper. Imaging results were correlated with histopathology. In the results, the tumor size was not significantly different in the treatment groups when compared to the control group on day 2 after therapy onset (P = 0.09). In contrast the imaging modalities DWI, DCE-MRI and
FDG
-PET showed significant differences between the therapeutic compared to the control group as early as 2 days after therapy onset (P<0.001). There was a strong correlation of the early changes in DWI, DCE-MRI and
FDG
-PET at day 2 after therapy onset and the change in tumor size at the end of therapy (r = -0.58, 0.71 and 0.67 respectively). The imaging results were confirmed by histopathology, showing early necrosis and necroptosis in the tumors. Thus multimodality multiparametric imaging was able to predict therapeutic success of PRS-050-PEG40 and Avastin as early as 2 days after onset of therapy and thus promising for monitoring early response of antiangiogenic therapy.
...
PMID:Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins. 2480 9
Gastric carcinosarcoma is a rare, malignant neoplasm that simultaneously comprises mixed epithelial and mesenchymal elements. In the present study, we report a case of gastric carcinosarcoma composed of
rhabdomyosarcoma
and adenocarcinoma on F-
FDG
PET/CT.
...
PMID:Gastric Carcinosarcoma and 18F-FDG PET/CT. 2635 57
Primary liver carcinosarcoma is a very rare, malignant neoplasm that is concomitantly composed of a mixture of sarcomatous and carcinomatous elements. In the present study, an initial staging
FDG
PET/CT showed intense
FDG
uptake in a patient with liver carcinosarcoma composed of hepatocellular carcinoma and
rhabdomyosarcoma
. Two months after surgical resection, a restaging PET/CT showed rapid progression of the disease with abdominal and lung metastases, indicating aggressive feature of the disease. The case shows the importance to repeat a restaging PET/CT at early time after surgery for a patient with liver carcinosarcoma to monitor disease progression.
...
PMID:Primary Liver Carcinosarcoma and 18F-FDG PET/CT. 2728 Sep 2
Considerable debate remains regarding how best to incorporate
18
F-
FDG
-PET/CT into clinical practice for pediatric sarcomas. Although there is a clear role for
18
F-
FDG
-PET/CT in staging pediatric sarcoma, the value of
18
F-
FDG
-PET/CT in prognostication for pediatric sarcomas remains unclear. In osteosarcoma, Ewing sarcoma, and
rhabdomyosarcoma
,
18
F-
FDG
-PET/CT may be most useful in the identification of skeletal metastases, where the literature consistently suggests that it has improved sensitivity and specificity as compared to bone scintigraphy. The role of the imaging modality in the identification of pulmonary metastatic disease is less clear. Further controversy exists regarding the use of
18
F-
FDG
-PET/CT in predicting outcome. Several studies, particularly in osteosarcoma, suggest changes in the maximal standardized uptake value (SUV
max
) that can predict histologic response following neoadjuvant chemotherapy as well as overall outcome. Conversely, studies are conflicting regarding the use of
18
F-
FDG
-PET/CT as a prognostic tool in Ewing sarcoma and
rhabdomyosarcoma
. The role of
18
F-
FDG
-PET/CT in pediatric nonrhabdomyosarcoma soft tissue sarcomas is unknown at this time. Although most studies have been small and retrospective, in certain histologic subtypes, there is a clear role for the use of this imaging modality. Additional prospective and larger studies are needed to fully determine how best to incorporate
18
F-
FDG
-PET/CT into treatment regimens for pediatric sarcomas in the future.
...
PMID:The Role of
18
F-FDG-PET/CT in Pediatric Sarcoma. 2841 53
A 38-year-old woman was referred for staging of an alveolar
rhabdomyosarcoma
revealed by a breast metastasis with unknown primary. Whole-body F-
FDG
PET/CT localized the primary tumor as an asymptomatic soft tissue lesion of the right foot with a significant uptake. PET/CT detected hepatic and pancreatic metastases and also showed a multifocal bone marrow involvement, which was not detected by the contrast-enhanced CT. These results led to a significant change in treatment management as the patient received local radiotherapy of the primitive lesion and polychemotherapy.
...
PMID:Rhabdomyosarcoma Revealed by a Breast Metastasis. 2935 38
1
2
Next >>
